Related Experiment Video
Updated: Aug 2, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Increased rates of intensive care unit admission in patients with Mycoplasma pneumoniae: a retrospective study
T Khoury1, S Sviri2, A A Rmeileh1
1Division of Medicine, Hadassah-Hebrew University Medical Centre, Ein Kerem, Jerusalem, Israel.
Abstract:
Mycoplasma pneumoniae is a leading cause of respiratory disease. In the Intensive Care Unit (ICU) setting M. pneumoniae is not considered a common pathogen. In 2010-13 an epidemic of M. pneumoniae-associated infections was reported and we observed an increase of M. pneumoniae patients admitted to ICU. We analysed the cohort of all M. pneumoniae-positive patients' admissions during 2007 to 2012 at the Hadassah-Hebrew University Medical Centre (a 1100-bed tertiary medical centre). Mycoplasma pneumoniae diagnosis was made routinely using PCR on throat swabs and other respiratory samples. Clinical parameters were retrospectively extracted. We identified 416 M. pneumoniae-infected patients; of which 68 (16.3%) were admitted to ICU. Of these, 48% (173/416) were paediatric patients with ICU admission rate of 4.6% (8/173). In the 19- to 65-year age group ICU admission rate rose to 18% (32/171), and to 38.8% (28/72) for patients older than 65 years. The mean APACHE II score on ICU admission was 20, with a median ICU stay of 7 days, and median hospital stay of 11.5 days. Of the ICU-admitted patients, 54.4% (37/68) were mechanically ventilated upon ICU admission. In 38.2% (26/68), additional pathogens were identified mostly later as secondary pathogens. A concomitant cardiac manifestation occurred in up to 36.8% (25/68) of patients. The in-hospital mortality was 29.4% (20/68) and correlated with APACHE II score. Contrary to previous reports, a substantial proportion (16.3%) of our M. pneumoniae-infected patients required ICU admission, especially in the adult population, with significant morbidity and mortality.
Insights
Mycoplasma pneumoniae infections, typically mild, increasingly require Intensive Care Unit (ICU) admission, especially in adults. This study highlights significant ICU-associated morbidity and mortality from M. pneumoniae.
Area of Science:
- Infectious Diseases
- Critical Care Medicine
- Pulmonology
Background:
- Mycoplasma pneumoniae is a common cause of respiratory illness.
- It is not typically considered a frequent pathogen in Intensive Care Units (ICUs).
- An epidemic from 2010-2013 indicated a potential rise in severe M. pneumoniae cases.
Purpose of the Study:
- To analyze the characteristics and outcomes of Mycoplasma pneumoniae patients admitted to the ICU.
- To determine the incidence and risk factors for ICU admission in M. pneumoniae infections.
- To assess the morbidity and mortality associated with severe M. pneumoniae cases.
Main Methods:
- Retrospective cohort study of M. pneumoniae-positive admissions from 2007-2012.
- Diagnosis confirmed by Polymerase Chain Reaction (PCR) on respiratory samples.
- Clinical data, including APACHE II scores and outcomes, were extracted.
Main Results:
- 16.3% of 416 M. pneumoniae patients required ICU admission.
- ICU admission rates were higher in adults (18% for 19-65 years, 38.8% for >65 years) compared to pediatric patients (4.6%).
- ICU patients had a mean APACHE II score of 20, 54.4% required mechanical ventilation, 36.8% had cardiac issues, and in-hospital mortality was 29.4%.
Conclusions:
- Contrary to prior beliefs, M. pneumoniae frequently necessitates ICU admission, particularly in adults.
- These severe cases exhibit significant morbidity, including high rates of mechanical ventilation and cardiac complications.
- The study underscores the critical illness potential of M. pneumoniae and its associated mortality risk.
Related Concept Videos
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia II: Pathophysiology
Pneumonia III: Complications and Assessment
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Atypical Pneumonia
Pneumonia I: Introduction
